ARCHIVES

ODAC Member Critical Of Amgen For Price Incentives.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

In Brief: HHS Won’t Nominate Fischbach for NIH; Kirschstein in Charge

April 28, 2000

FDA Pettiness Holds Up Trials with Promising Anticancer Drugs

November 14, 1975

Komen, ACS Support Payment Off-Protocol; Dilemma for Advocates

April 16, 1999

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

In Brief: Search Committee Could Finish Job Weeks, Perry Says Nominations Are Being Solicited

January 11, 1980

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013